AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01020994 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LAS189961
Description: Once daily, topically
Study NCT01523613 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Chemfil ROCK Glassionomer restoration
Description: High-viscous glassionomer restoration of Chemfil ROCK used as posterior dental filling material.
Study NCT01523613 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fuji IX GP Extra Glassionomer restoration
Description: High-viscous glassionomer restoration of Fuji IX GP Extra used as posterior dental filling material.
Study NCT04346368 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BM-MSCs
Description: Participants will receive conventional treatment plus BM-MSCs(1\*10E6 /kg body weight intravenously at Day 1).
Study NCT04346368 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT00095836 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefitinib
Description: Taken orally once a day for duration of benefit. Treatment is continuous until there is evidence of disease progression or unacceptable toxicity.
Study NCT02733276 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: electroacupuncture
Description: Electroacupuncture: Using an electroacupuntor with different frequencies during 20 minutes. Needles are connected to the electrodes.
Study NCT02733276 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham: Electroacupuncture sham
Description: Sham comparator (Electroacupuncture sham): Using an electroacupuntor with different frequencies during 20 minutes. Needles are connected to the electrodes.
Study NCT01041885 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: INSTRUCT
Description: INSTRUCT PolyActive scaffold implantation
Study NCT00419029 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: telephone-administered motivational interviewing
Description: telephone motivational interviewing
Study NCT00419029 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: control
Description: brief telephone check-in (no motivational interviewing)
Study NCT01584115 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NY-ESO-1 combined with MPLA
Description: Each patient will receive six doses of the formulation, administered intra-muscular, with an interval of 4 weeks between doses, and the first immunization performed 6 weeks after the completion of standard treatment. NY-ESO-1 (250 mcg) amd MPLA (100 mcg).
Study NCT01584115 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NY-ESO-1 combined with MPLA vaccine
Description: Immunization os cancer patients with NY-ESO-1 combined with MPLA vaccine
Study NCT04509635 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Cetuximab is used for only patients with ctDNA test RAS wild type.
Study NCT01650051 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of Phenazopyridine Hydrochloride Tables, USP 200 mg
Description: Deep brown maroon colored, film coated round biconvex tablet debossed 'AN obve '2' on one side and plain on the other side.
Study NCT04509635 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: The detailed regimen is determined by a multi-disciplinary team according to the previous use of chemotherapy.
Study NCT04509635 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy
Description: The detailed regimen is determined by a multi-disciplinary team according to the previous use of chemotherapy.
Study NCT00856115 — intervention group
Intervention type: OTHER
Intervention: medical chart review
Description: Patient charts are reviewed to obtain medical data.
Study NCT01650051 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenazopyridine Hydrochloride Tables, USP 200 mg
Description: Deep brown maroon colored, film coated round biconvex tablet debossed 'AN obve '2' on one side and plain on the other side.
Study NCT05566457 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Huangqi Guizhi Wuwu decoction (HGWD) infusion packs
Description: Patients in the HGWD group (n = 46) soaked and washed Immersion and Washing limbs with HGWD infusion packs, followed by smearing limbs with vitamin E and vitamin B12. The composition of HGWD infusion pack was: 60g Radix Astragali (Huangqi), 15g Ramulus Cinnamomi (Guizhi), 15g Paeonia lactiflora (Baishao), 15g Gentiana (Qinjiao), 6g Scorpio (Quan-Xie), 20g Rhizoma Zingiberis Recens (Shengjiang), 20 Jujubes (Dazao), 30g Geranium wilfordii (Laoguancao), 12g radix sileris (Fangfeng), 30g Spatholobus suberectus (Jixueteng), 15g Ligusticum (Chuanxiong), 15g Poria (Fuling), and 15g Radixcyathulae (Chuanniuxi). HGWD infusion pack was boiled in water and extraction was performed twice to obtain a total of 500 ml drug-containing water. The drug-containing water was maintained at 39 to 40℃ for soaking and washing limbs for 20min twice a day for consecutive 14 days
Study NCT02955966 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: imaging 18F-FDG-PET/CT
Description: 18F-FDG PET Scan at Day 0, W6 and W12
Study NCT02955966 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood collection
Description: Blood collection at D0, D3, W1, W2, W4, W6, W12, end of treatment.
Study NCT01475110 — intervention group
Intervention type: DRUG
Intervention: Imatinib
Description: Observation of Imatinib resistant patients treated with Nilotinib.
Study NCT00874588 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HLA-A*2402restricted URLC10, CDCA1, VEGFR1 and VEGFR2
Description: Escalating doses of every peptide will be administered by subcutaneous injection on days 1,8,15 and 22 of each 28-day treatment cycles. Planned doses of peptides are 1.0mg and 3.0mg.
Study NCT00532766 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Jusline
Study NCT02724735 — intervention group
Intervention type: DRUG
Intervention: NSI-189
Description: 0 Milligrams, 40 Milligrams or 80 Milligrams administered in the acute study only
Study NCT02668861 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: Vitamin D 4000IU/day for 8 weeks
Study NCT02668861 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide Nasal Spray
Description: Budesonide Nasal Spray 128ug/d for 8 week
Study NCT02668861 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Budesonide Nasal Spray
Description: Budesonide Nasal Spray 128ug/d for 8 week
Study NCT02668861 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo for 8 weeks
Study NCT04602767 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vasopressin
Description: Vasopressin titrated 0.01 U/min up to 0.04 U/min for MAP \< 65 mmHg
Study NCT04602767 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenylephrine
Description: Phenylephrine titrated 0.25 mcg/kg/min up to 1.0 mcg/kg/min for MAP \< 65 mmHg
Study NCT02488291 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.25 sufentanil
Description: with different dosage
Study NCT02488291 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.5µg/ml sufentanil
Description: 0.5µg/ml sufentanil
Study NCT02488291 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.1% ropivacaine
Description: 0.1% ropivacaine
Study NCT02168972 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Global mapping and ablation device
Description: During the procedure the Globe catheter will be delivered via standard femoral vein access and transseptal puncture. Anatomical and electrophysiological mapping of the LA will be followed by pulmonary vein isolation (PVI) by RF ablation. Additional lesions will be created as deemed appropriate by the investigator.
Study NCT00989391 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-03654764
Description: 5mg orally once daily for 10 days. After satisfactory review of the available safety, toleration and PK data, progression to the next dose will occur if the last dose was well tolerated. If the previous dose was not well tolerated, after review of the safety data, and discussion between the Pfizer Study Team and the Investigator, the same dose may be given again, a lower dose within the tolerated dose range may be given, or the study may be stopped. The dose increments will be based on emerging safety and toleration data, as well as plasma exposure estimates and forward predictions of PK. Nominal administered doses will not exceed 24 mg per day.
Study NCT02915783 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenvatinib
Description: 4 mg and 10 mg capsules
Study NCT02915783 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: everolimus
Description: 5 mg tablets
Study NCT02541305 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: propioceptive program
Description: The training program has 6 specific proprioceptive exercises, each five minutes long, which will conducted in static and dynamic positions for a period of 30 minutes. Each exercise session will include 55 minutes (15 minutes of warm-up with slow walk, mobility and stretching exercise, followed by 30 minutes of a propioceptive exercises program, and finishing with 10 minutes of cool down through stretching and relaxation exercises)
Study NCT02541305 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No propioceptive program
Description: The control group continued to perform their daily activities without changing any habit. Geriatric revitalization program without proprioceptive exercises.
Study NCT03009344 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tazemetostat
Description: Tazemetostat tablets.
Study NCT03507244 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Pemetrexed, 10 mg,intrathecal injection, plus dexamethasone 5 mg, once per week, 5 to 8 times, 4 to 7 weeks in total.
Study NCT03507244 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone, 5 mg, intrathecal injection, simultaneously with pemetrexed, once per week, 5 to 8 times, 4 to 7 weeks in total.
Study NCT03507244 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: The sites of symptomatic disease, bulky disease observed on MRI, including the whole brain and basis cranii, 40 Gy in 20 fractions;and/or segment of spinal canal received 40-50 Gy in 20-25 fractions.
Study NCT04106739 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Drug Relief V(version) 2.0 Auricular Percutaneous Electrical Neural Field Stimulation (PENFS)
Description: This is a Small electronic circuit board with a minimal number of electronic components in it, which is powered by three zinc-air batteries. Each battery consists of 1.4v of charge. From this charge, the circuit produces a maximum voltage of 3.4V under no load condition.~The produced Voltage is driven as output by using the three stimulation wires, and the fourth insulated wire acts as a ground. The wires are Bio-compatible and do not have any impact when in contact with the human skin. The wire is attached with a needle to transfer the produced voltage into the nerves of the human ear. The sterilized needle (Titanium) is attached at the end of the wire through a snap fit ring. All the materials used are gone through necessary safety and performance testing including bio-compatibility and sterility testing, wherever necessary.
Study NCT04106739 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Drug Relief V(version) 2.0 Auricular Percutaneous Electrical Neural Field Stimulation (PENFS)
Description: This is a Small electronic circuit board with a minimal number of electronic components in it, which is powered by three zinc-air batteries. Each battery consists of 1.4v of charge. From this charge, the circuit produces a maximum voltage of 3.4V under no load condition.~The produced Voltage is driven as output by using the three stimulation wires, and the fourth insulated wire acts as a ground. The wires are Bio-compatible and do not have any impact when in contact with the human skin. The wire is attached with a needle to transfer the produced voltage into the nerves of the human ear. The sterilized needle (Titanium) is attached at the end of the wire through a snap fit ring. All the materials used are gone through necessary safety and performance testing including bio-compatibility and sterility testing, wherever necessary.
Study NCT01971255 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ca/04/2009/H1N1r Challenge Virus
Description: The human challenge virus will be administered intranasally to each participant using a nasal sprayer. A total volume of up to 1 mL of virus will be administered.
Study NCT01802619 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: inhaled nitric oxide
Description: Nitric oxide administration will commence at the onset of CPB and last for 24 hours. At the end of 24 hours, inhaled NO will be weaned and discontinued while carefully monitoring hemodynamics for a period of 2-4 hours.
Study NCT01802619 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: inhaled Nitrogen
Description: Standard gas including nitrogen (the vehicle of the Nitric oxide) administration will commence at the onset of CPB and last for 24 hours. At the end of 24 hours, inhaled gases will be weaned and discontinued while carefully monitoring hemodynamics for a period of 2-4 hours.
Study NCT05330000 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 4 mg/kg Voriconazole
Description: Low dose group: 24 healthy adult subjects are planned to be enrolled. Intravenous drip Voriconazole for injection in fasting state per cycle. The dosage was 4 mg / kg for 80 min.
Study NCT05330000 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4 mg/kg Voriconazole
Description: Low dose group: 24 healthy adult subjects are planned to be enrolled. Intravenous drip Voriconazole for injection in fasting state per cycle. The dosage was 4 mg / kg for 80 min.
Study NCT00989391 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: orally once daily for 10 days. After satisfactory review of the available safety, toleration and PK data, progression to the next dose will occur if the last dose was well tolerated. If the previous dose was not well tolerated, after review of the safety data, and discussion between the Pfizer Study Team and the Investigator, the same dose may be given again, a lower dose within the tolerated dose range may be given, or the study may be stopped. The dose increments will be based on emerging safety and toleration data, as well as plasma exposure estimates and forward predictions of PK. Nominal administered doses will not exceed 24 mg per day.
Study NCT05330000 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 6 mg/kg Voriconazole
Description: High dose group: 24 healthy adult subjects are planned to be enrolled. Intravenous drip Voriconazole for injection in fasting state per cycle. The dosage was 6 mg / kg for 120 min.
Study NCT05330000 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 6 mg/kg Voriconazole
Description: High dose group: 24 healthy adult subjects are planned to be enrolled. Intravenous drip Voriconazole for injection in fasting state per cycle. The dosage was 6 mg / kg for 120 min.
Study NCT04405310 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Convalescent Plasma of patients with COVID-19
Description: Convalescent Plasma from patients with covid-19 by Apheresis, the maximum plasma volume withdrawn per session should not exceed 600 mL, excluding the anticoagulant volume, or 16% of the total blood volume, in the absence of volumetric replacement.
Study NCT04405310 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo (hartmann plus albumine)
Description: use of albumin 20% in 250cc of Hartmann solution
Study NCT02684435 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perflutren lipid microsphere
Description: Dosing per approved package label
Study NCT01862159 — intervention group
Intervention type: PROCEDURE
Intervention: laparoscopic gastric bypass surgery
Description: laparoscopic gastric bypass surgery
Study NCT00856115 — intervention group
Intervention type: OTHER
Intervention: questionnaire administration
Description: Patients undergo a 45-60 minute interview to obtain information on variations in symptom perception, assessment, and patient-physician communication process. Patients are assessed by sociodemographic characteristics (i.e, education, gender, age, insurance status, employment status, income, race/ethnicity, and religiosity), information of close confidants (i.e., relationship, family history of cancer, and caregiver/decision-making status), and physician characteristics. Patients are also assessed by the Trust in the Health Care System, DMPQ, RCS, Brief COPE scale, Lukwago Religiosity scale, and RAND Social Support Survey questionnaires.
Study NCT00856115 — intervention group
Intervention type: OTHER
Intervention: study of socioeconomic and demographic variables
Description: Patients are assessed by sociodemographic characteristics (i.e, education, gender, age, insurance status, employment status, income, race/ethnicity, and religiosity).
Study NCT00856115 — intervention group
Intervention type: OTHER
Intervention: survey administration
Description: Patients are also assessed by the Trust in the Health Care System, DMPQ, RCS, Brief COPE scale, Lukwago Religiosity scale, and RAND Social Support Survey questionnaires.
Study NCT03210415 — intervention group
Intervention type: OTHER
Intervention: Observational Study Model
Description: There is no intervention for the study.
Study NCT04107935 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TREAT-ON
Description: TREAT-ON is a DE-driven self-management and support program that is delivered primarily through a real-time telemedicine videoconferencing platform. Like the usual care intervention, high risk patients with DM receiving care in underserved practices will be identified by a nurse practice-based manager (PCBM) and referred to a DE for self management services. Participants will complete an initial face-to-face visit with the DE to assess needs and develop a self-management treatment plan and goals. Via telemedicine videoconferencing, follow-up visits will be delivered by the DE to participants in their homes. Follow-up visits will be used to evaluate and support progress towards meeting and sustaining self-management goals and outcomes.
Study NCT04107935 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Usual Care
Description: A retrospective control group will be formed from individuals who have previously participated in a program called the Diabetes High Risk Initiative. In this program, patients receiving care in underserved practices are identified by a nurse PBCM to be at high risk for DM complications and/or unplanned care and referred to a DE for self management services delivered through primary care. Patients typically participate in one face-to-face visit with the DE to assess needs and develop self-management goals and then one to two follow-up encounters (generally conducted by telephone) with the PBCM or DE.
Study NCT02169726 — intervention group
Intervention type: DEVICE
Intervention: Diffuse Optical Spectroscopy
Description: Diffuse Optical Spectroscopy Imaging measure blood flow,oxygen, temperature in back muscle when they are treated with therapeutic ultrasound and can improve the treatment
Study NCT03795051 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Navigated Transcranial Magnetic Stimulation
Description: This study is a feasibility trial. Each participant will receive 30sessions of 10 Hz or 20 Hz rTMS over the left DLPFC. The rTMS interventions will be guided by a neuronavigation system (StimGuide TMS Navigation System, Magstim, Ltd. Carmarthenshire, UK) for navigation to the treatment location and to ensure consistent placement and orientation of the coil during and between each session. For the purpose of this protocol, these sessions are referred to as nTMS.
Study NCT03062605 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iodine (Betadine)
Study NCT03062605 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: NaOCL
Study NCT01009333 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: InterStim Therapy at rate 5.2 Hz
Description: All subjects enrolled in this study were programmed to this rate setting for a 1-week period.
Study NCT01009333 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: InterStim Therapy at rate 14 Hz
Description: All subjects enrolled in this study were programmed to this rate setting for a 1-week period.
Study NCT01009333 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: InterStim Therapy
Description: All subjects enrolled in this study were programmed to each rate setting (low, medium, high) for a 1-week period.
Study NCT04046666 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Functional near infrared spectroscopy
Description: Functional near infrared spectroscopy will be adopted to assess the metabolic characteristics of the Heart and Lung meridians. The probes will be left at 4 measurement sites, which include Shenmen (HT7) and Shaohai (HT3) of the Heart meridian, Taiyuan (LU9) and Chize (LU5) of the Lung meridian.
Study NCT04046666 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Moxibustion
Description: Two sessions of moxibustion will be performed in the Heart meridian and Lung meridian successively.~Intervention in the Heart meridian: moxibustion will be performed above Shaohai (HT3) for 15 minutes. During moxibustion, the probes of near infrared spectroscopy will detect the metabolic characteristics of three measuring sites, which include the midpoint of the Heart meridian along the forearm, Chize (LU5) of the Lung meridian, and the midpoint of the Lung meridian along the forearm.~Intervention in the Lung meridian: moxibustion will be performed above Chize (LU5) for 15 minutes. During moxibustion, the probes of near infrared spectroscopy will detect the metabolic characteristics of three measuring sites, which include the midpoint of the Lung meridian along the left forearm, Shaohai (HT3) of the Heart meridian, and the midpoint of the Heart meridian along the forearm.